Research |

 Relevant Publications

 

1

 

The following research publications were supported by the Centre:

1. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.
Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI.
Mol Cancer Ther. 2018 Aug;17(8):1670-1682. doi: 10.1158/1535-7163.MCT-18-0010. Epub 2018 Jun 11.
2. Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI.
Cancer Res. 2018 Jun 1;78(11):3054-3066. doi: 10.1158/0008-5472.CAN-17-3932. Epub 2018 May 7.
3. A case of lymphangioma-like mesenteric cysts diagnosed as adenocarcinoma of possible pancreatic origin on EUS-FNA.
Delvincourt M, Godfrey EM, Duckworth A, Carroll NR.
Gastrointest Endosc. 2018 May;87(5):1359-1361. doi: 10.1016/j.gie.2017.10.036. Epub 2017 Nov 4. No abstract available.
4. Multicenter experience from the UK and Ireland of use of lumen-apposing metal stent for transluminal drainage of pancreatic fluid collections.
Venkatachalapathy SV, Bekkali N, Pereira S, Johnson G, Oppong K, Nayar M, Leeds J, Paranandi B, Penman I, Carroll N, Godfrey E, James M, Aithal G, McKay C, Devlin J, Wong T, Makin A, Ryan B, Huggett M.
Endosc Int Open. 2018 Mar;6(3):E259-E265. doi: 10.1055/s-0043-125362. Epub 2018 Feb 28.
5. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D.
Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13.
6. Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.
Feretis M, Wang T, Iype S, Duckworth A, Brais R, Basu B, Jamieson NV, Huguet E, Balakrishnan A, Jah A, Praseedom RK, Harper SJ, Liau SS.
Pancreas. 2017 Nov/Dec;46(10):1314-1321. doi: 10.1097/MPA.0000000000000929.
7. Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
Narvaez AJ, Ber S, Crooks A, Emery A, Hardwick B, Guarino Almeida E, Huggins DJ, Perera D, Roberts-Thomson M, Azzarelli R, Hood FE, Prior IA, Walker DW, Boyce R, Boyle RG, Barker SP, Torrance CJ, McKenzie GJ, Venkitaraman AR.
Cell Chem Biol. 2017 Aug 17;24(8):1017-1028.e7. doi: 10.1016/j.chembiol.2017.07.009. Epub 2017 Aug 10.
8. Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis.
Sivakumar S, de Santiago I, Chlon L, Markowetz F.
PLoS Med. 2017 Jan 31;14(1):e1002223. doi: 10.1371/journal.pmed.1002223. eCollection 2017 Jan.
9. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.
Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.
Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010.
10. Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.
Perera D, Venkitaraman AR.
Sci Rep. 2016 Jul 14;6:29741. doi: 10.1038/srep29741.
11. CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.
Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI.
Cancer Res. 2015 Sep 1;75(17):3583-95. doi: 10.1158/0008-5472.CAN-14-3347. Epub 2015 Jul 3.
12. First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U.
Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422. Epub 2015 Mar 24.
13. Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma.
Cook N, Brais R, Qian W, Hak CC, Corrie PG.
J Clin Pathol. 2015 Apr;68(4):309-13. doi: 10.1136/jclinpath-2014-202521. Epub 2015 Jan 8.
14. Negative predictive value of drain amylase concentration for development of pancreatic fistula after pancreaticoduodenectomy.
Zelga P, Ali JM, Brais R, Harper SJ, Liau SS, Huguet EL, Jamieson NV, Praseedom RK, Jah A.
Pancreatology. 2015 Mar-Apr;15(2):179-84. doi: 10.1016/j.pan.2014.12.003. Epub 2014 Dec 30.
15. Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Elias A, Chatzizacharias NA, Xanthis A, Corrie P, Davies S, Brais RJ, Jamieson NV, Praseedom RK, Huguet E, Harper SJ, Jah A.
Medicine (Baltimore). 2015 Feb;94(6):e499. doi: 10.1097/MD.0000000000000499.

More Publications →